Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Biobased chemicals firm Genomatica has raised $41.5 million in a fourth round of funding from new investor Versalis, the chemical arm of Italy’s Eni, as well as existing venture capital investors. At the same time, Genomatica has withdrawn its August 2011 filing with the Securities & Exchange Commission for an initial public offering of stock. It plans instead to commercialize its first products with the help of strategic partners and private investors. Genomatica’s technology uses genetically modified Escherichia coli to produce chemicals, including butanediol and butadiene, from sugar.
This article has been sent to the following recipient: